Category
Clinical guidelines and protocols
Guidelines translate evidence into instructions, and in doing so shape uptake as powerfully as reimbursement does. This coverage follows new and revised guidance and the evidence behind it.
326 articles in this topic.
Articles in this category

10/23/2026
FDA Launches Neuroscience Medical Product Development Program
The FDA has launched the Neuroscience Advancement and Innovation Nexus, starting with an Alzheimer's Prevention Accelerator. #SyenzaNews #Alzheimers #MarketAccess
Read Article →
10/23/2026
Clinical AI governance framework guides AI tool evaluation
A new npj Digital Medicine article in press from SCPMG proposes the C-TACT clinical AI governance framework, with weighted lifecycle scorecards and its limits stated.
Read Article →
10/16/2026
AI operating room scheduling: LLM agent teams reach feasible plans
How can AI-powered scheduling transform operating room efficiency and deliver major cost savings?
Recent advancements are enabling hospitals to optimize resource allocation, reduce cancellations, and streamline workflows through intelligent automation.
Discover how this technology is reshaping surgical operations and improving financial outcomes.
#SyenzaNews #AIinHealthcare #HealthcareInnovation #ai #DigitalTransformation
Read Article →
10/15/2026
FDA Rare Disease Framework Initiative Would Tailor Review to Small Populations
What steps is the FDA taking to accelerate rare disease treatments?
The FDA’s new Rare Disease Framework Initiative aims to streamline regulatory pathways, enhance collaboration with sponsors, and improve patient access to innovative therapies.
Explore how this could reshape drug development for underserved patient populations.
#SyenzaNews #regulatoryaffairs #drugdevelopment #innovation #healthcarepolicy
Read Article →
10/13/2026
Individualised Genetic Therapies Test Regulation, Payment and HTA
OHE's A Dose of Economics explores why medicines made for one patient challenge regulation, payment and HTA.
Read Article →
10/12/2026
AI in Medical Education: Responsible Integration Across the Training Continuum
AI is entering every stage of medical training. A new npj Digital Medicine Perspective maps how to integrate it responsibly across UGME, GME and CME.
Read Article →
9/10/2026
UK Commission Sets Out a Framework for AI Healthcare Regulation
An independent UK commission has published its recommendations for regulating AI in healthcare. The report calls for staged approvals and continuous real-world monitoring, alongside stronger enforcement powers for the MHRA. #SyenzaNews #AI #Healthcare #MarketAccess
Read Article →
9/2/2026
Nirmatrelvir-Ritonavir Long COVID Treatment Shows No Benefit in RECOVER-VITAL
The RECOVER-VITAL trial found nirmatrelvir-ritonavir offered no benefit for long COVID across cognitive, autonomic, or exercise symptoms. The study also shows why placebo controls matter: a large share of the placebo group improved on their own. #SyenzaNews #LongCOVID #ClinicalTrials #MarketAccess
Read Article →
8/31/2026
Linking Drug and Diagnostic Policy Pathways to Reach Patients Most Likely to Benefit
Insurers are spending billions on breakthrough medicines, but the tests that decide who gets them are still an afterthought. Kathryn Phillips lays out four reforms to link drug and diagnostic policy pathways. #SyenzaNews #diagnostics #healtheconomics #MarketAccess
Read Article →
8/31/2026
AI Models Near Perfect Scores on German Medical Licensing Exams
A new benchmark in npj Digital Medicine finds frontier AI models at near-perfect accuracy on German medical licensing exams, yet image questions still cut their scores far more than for students. #SyenzaNews #AIinHealthcare #DigitalHealth
Read Article →
8/24/2026
New DISH Surgical Classification System Standardises Wound Outcome Reporting
A new consensus framework grades dehiscence, infection, seroma, and haematoma in a single score, with strong agreement across 60 specialists.
Read Article →
8/21/2026
FDA Opens Docket for Input on Generative AI Medical Devices
The FDA has opened a public consultation on regulating generative AI medical devices, proposing a two-axis risk framework and a competency-based approach to premarket review. Comments close 19 October 2026.
Read Article →

